{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:44:37Z","timestamp":1792079077038,"version":"4.4.0"},"reference-count":62,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2025,11,30]]},"DOI":"10.5582\/irdr.2025.01051","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T22:08:32Z","timestamp":1759442912000},"page":"249-257","source":"Crossref","is-referenced-by-count":3,"title":["Mitochondrial DNA A3243G variant: Current perspectives and clinical implications"],"prefix":"10.5582","volume":"14","author":[{"given":"Kuan-Yu","family":"Chu","sequence":"first","affiliation":[{"name":"School of Dentistry and Graduated Institute of Dental Science, College of Oral Medicine, National Defense Medical University, Taipei, Taiwan."},{"name":"Interdisciplinary Education Center, MacKay Junior College of Medicine, Nursing and Management, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Battista V, Koenigsberger DY, Pascual JM, Sano M, Hirano M, DiMauro S, Shungu DC, Mao X, De Vivo DC. Protein phenotypic features of the A3243G mitochondrial DNA mutation. Arch Neurol. 2009; 66:85-91.","DOI":"10.1001\/archneurol.2008.526"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Coussa RG, Parikh S, Traboulsi EI. Mitochondrial DNA A3243G variant-associated retinopathy: Current perspectives and clinical implications. Surv Ophthalmol. 2021; 66:838-855.","DOI":"10.1016\/j.survophthal.2021.02.008"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Abad MM, Cotter PD, Fodor FH, Larson S, Ginsberg-Fellner F, Desnick RJ, Abdenur JE. Screening for the mitochondrial DNA A3243G mutation in children with insulin-dependent diabetes mellitus. Metabolism. 1997; 46:445-449.","DOI":"10.1016\/S0026-0495(97)90064-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Li R, Guan MX. Human mitochondrial leucyl-tRNA synthetase corrects mitochondrial dysfunctions due to the tRNA<sup>Leu(UUR)<\/sup> A3243G mutation, associated with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms and diabetes. Mol Cell Biol. 2010; 30:2147-2154.","DOI":"10.1128\/MCB.01614-09"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Daruich A, Matet A, Borruat FX. Macular dystrophy associated with the mitochondrial DNA A3243G mutation: Pericentral pigment deposits or atrophy? Report of two cases and review of the literature. BMC Ophthalmol. 2014; 14:77.","DOI":"10.1186\/1471-2415-14-77"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Jeppesen TD, Schwartz M, Frederiksen AL, Wibrand F, Olsen DB, Vissing J. Muscle phenotype and mutation load in 51 persons with the 3243A&gt;G mitochondrial DNA mutation. Arch Neurol. 2006; 63:1701-1706.","DOI":"10.1001\/archneur.63.12.1701"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Koga Y, Povalko N, Nishioka J, Katayama K, Yatsuga S, Matsuishi T. Molecular pathology of MELAS and L-arginine effects. Biochim Biophys Acta. 2012; 1820:608-614.","DOI":"10.1016\/j.bbagen.2011.09.005"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kamble AS, Fandilolu PM, Sambhare SB, Sonawane KD. Idiosyncratic recognition of UUG\/UUA codons by modified nucleoside 5-taurinomethyluridine, \u03c4m5U present at &apos;wobble&apos; position in anticodon loop of tRNALeu: A molecular modeling approach. PLoS One. 2017; 12:e0176756.","DOI":"10.1371\/journal.pone.0176756"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cox BC, Pearson JY, Mandrekar J, Gavrilova RH. The clinical spectrum of MELAS and associated disorders across ages: A retrospective cohort study. Front Neurol. 2023; 14:1298569.","DOI":"10.3389\/fneur.2023.1298569"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Koopman WJ, Willems PH, Smeitink JA. Monogenic mitochondrial disorders. N Engl J Med. 2012; 366:1132-1141.","DOI":"10.1056\/NEJMra1012478"},{"key":"11","unstructured":"11. Lafor\u00eat P, Ziegler F, Sternberg D, Rouche A, Frachon P, Fardeau M, Eymard B, Lomb\u00e8s A. [&quot;MELAS&quot; (A3243G) mutation of mitochondrial DNA: A study of the relationships between the clinical phenotype in 19 patients and morphological and molecular data]. Rev Neurol (Paris). 2000; 156:1136-1147."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Koga Y, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T. MELAS and l-arginine therapy: Pathophysiology of stroke-like episodes. Ann N Y Acad Sci. 2010; 1201:104-110.","DOI":"10.1111\/j.1749-6632.2010.05624.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lin DS, Huang YW, Ho CS, Huang TS, Lee TH, Wu TY, Huang ZD, Wang TJ. Impact of mitochondrial A3243G heteroplasmy on mitochondrial bioenergetics and dynamics of directly reprogrammed MELAS neurons. Cells. 2022; 12:15.","DOI":"10.3390\/cells12010015"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gu\u00e9ry B, Choukroun G, No\u00ebl LH, Clavel P, R\u00f6tig A, Lebon S, Rustin P, Bellan\u00e9-Chantelot C, Mougenot B, Gr\u00fcnfeld JP, Chauveau D. The spectrum of systemic involvement in adults presenting with renal lesion and mitochondrial <i>tRNA<sup>Leu<\/sup><\/i> gene mutation. J Am Soc Nephrol. 2003; 14:2099-2108.","DOI":"10.1097\/01.ASN.0000080180.51098.02"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Vuorinen AM, Lehmonen L, Auranen M, Weckstr\u00f6m S, Kivist\u00f6 S, Holmstr\u00f6m M, Heli\u00f6, T. Cardiac involvement in patients with MELAS-Related mtDNA 3243A&gt;G variant. Cardiogenetics. 2025; 15:16.","DOI":"10.3390\/cardiogenetics15020016"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Wai T, Teoli D, Shoubridge EA. The mitochondrial DNA genetic bottleneck results from replication of a subpopulation of genomes. Nat Genet. 2008; 40:1484-1488.","DOI":"10.1038\/ng.258"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Stewart JB, Chinnery PF. The dynamics of mitochondrial DNA heteroplasmy: Implications for human health and disease. Nat Rev Genet. 2015; 16:530-542.","DOI":"10.1038\/nrg3966"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Rossignol R, Faustin B, Rocher C, Malgat M, Mazat JP, Letellier T. Mitochondrial threshold effects. Biochem J. 2003; 370:751-762.","DOI":"10.1042\/bj20021594"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Chinnery PF, Samuels DC. Relaxed replication of mtDNA: A model with implications for the expression of disease. Am J Hum Genet. 1999; 64:1158-1165.","DOI":"10.1086\/302311"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Schwartz M, Vissing J. Paternal inheritance of mitochondrial DNA. N Engl J Med. 2002; 347:576-580.","DOI":"10.1056\/NEJMoa020350"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Poulton J, Marchington DR. Segregation of mitochondrial DNA (mtDNA) in human oocytes and in animal models of mtDNA disease: Clinical implications. Reproduction. 2002; 123:751-755.","DOI":"10.1530\/rep.0.1230751"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Rahman S, Poulton J, Marchington D, Suomalainen A. Decrease of 3243A--&gt;G mtDNA mutation from blood in MELAS syndrome: A longitudinal study. Am J Hum Genet. 2001; 68:238-240.","DOI":"10.1086\/316930"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. McDonnell MT, Schaefer AM, Blakely EL, McFarland R, Chinnery PF, Turnbull DM, Taylor RW. Noninvasive diagnosis of the 3243A&gt;G mitochondrial DNA mutation using urinary epithelial cells. Eur J Hum Genet. 2004; 12:778-781.","DOI":"10.1038\/sj.ejhg.5201216"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Cree LM, Samuels DC, de Sousa Lopes SC, Rajasimha HK, Wonnapinij P, Mann JR, Dahl HH, Chinnery PF. A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nat Genet. 2008; 40:249-254.","DOI":"10.1038\/ng.2007.63"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Freyer C, Cree LM, Mourier A, Stewart JB, Koolmeister C, Milenkovic D, Wai T, Floros VI, Hagstr\u00f6m E, Chatzidaki EE, Wiesner RJ, Samuels DC, Larsson NG, Chinnery PF. Variation in germline mtDNA heteroplasmy is determined prenatally but modified during subsequent transmission. Nat Genet. 2012; 44:1282-1285.","DOI":"10.1038\/ng.2427"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Walters J, Baborie A. Muscle biopsy: What and why and when? Pract Neurol. 2020; 20:385-395.","DOI":"10.1136\/practneurol-2019-002465"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Lorenzoni PJ, Scola RH, Kay CS, Arndt RC, Freund AA, Bruck I, Santos ML, Werneck LC. MELAS: Clinical features, muscle biopsy and molecular genetics. Arq Neuropsiquiatr. 2009; 67:668-676.","DOI":"10.1590\/S0004-282X2009000400018"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Felczak P, Lewandowska E, St\u0119pniak I, O\u0142dak M, Pollak A, Lechowicz U, Pasennik E, St\u0119pie\u0144 T, Wierzba-Bobrowicz T. Pathology of mitochondria in MELAS syndrome: An ultrastructural study. Pol J Pathol. 2017; 68:173 -181.","DOI":"10.5114\/pjp.2017.65021"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Lorenzoni PJ, Werneck LC, Kay CSK, Silvado CES, Scola RH. When should MELAS (Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes) be the diagnosis? Arq Neuropsiquiatr. 2015; 73:959-967.","DOI":"10.1590\/0004-282X20150154"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kanaumi T, Hirose S, Goto Y, Naitou E, Mitsudome A. An infant with a mitochondrial A3243G mutation demonstrating the MELAS phenotype. Pediatr Neurol. 2006; 34:235-238.","DOI":"10.1016\/j.pediatrneurol.2005.08.024"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Majamaa K, Turkka J, K\u00e4rpp\u00e4 M, Winqvist S, Hassinen IE. The common MELAS mutation A3243G in mitochondrial DNA among young patients with an occipital brain infarct. Neurology. 1997; 49:1331-1334.","DOI":"10.1212\/WNL.49.5.1331"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Ng YS, Turnbull DM. Mitochondrial disease: Genetics and management. J Neurol. 2016; 263:179-191.","DOI":"10.1007\/s00415-015-7884-3"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Sue CM, Crimmins DS, Soo YS, Pamphlett R, Presgrave CM, Kotsimbos N, Jean-Francois MJ, Byrne E, Morris JG. Neuroradiological features of six kindreds with MELAS <i>tRNA<sup>Leu<\/sup><\/i> A2343G point mutation: Implications for pathogenesis. J Neurol Neurosurg Psychiatry. 1998; 65:233-240.","DOI":"10.1136\/jnnp.65.2.233"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Liu CH, Chang CH, Kuo HC, Ro LS, Liou CW, Wei YH, Huang CC. Prognosis of symptomatic patients with the A3243G mutation of mitochondrial DNA. J Formos Med Assoc. 2012; 111:489-494.","DOI":"10.1016\/j.jfma.2011.06.014"},{"key":"35","unstructured":"35. Zhang J, Guo J, Fang W, Jun Q, Shi K. Clinical features of MELAS and its relation with A3243G gene point mutation. Int J Clin Exp Pathol. 2015; 8:13411-13415."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Bukhari K, Pennant M. Mitochondrial diabetes: The clinical spectrum of MIDD and MELAS in association with the A3243G mutation. J Endocr Soc. 2021; 5:A392-A393.","DOI":"10.1210\/jendso\/bvab048.799"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Chanoine JP, Thompson DM, Lehman A. Diabetes associated with maternally inherited diabetes and deafness (MIDD): From pathogenic variant to phenotype. Diabetes. 2024; 74:153-163.","DOI":"10.2337\/db24-0515"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Zheng S, Wang J, Sun M, Wang P, Shi W, Zhang Z, Wang Z, Zhang H. The clinical and genetic characteristics of maternally inherited diabetes and deafness (MIDD) with mitochondrial m.3243A&gt;G mutation: A 10-year follow-up observation study and literature review. Clin Case Rep. 2024; 12:e8458.","DOI":"10.1002\/ccr3.8458"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Deschauer M, M\u00fcller T, Wieser T, Schulte-Mattler W, Kornhuber M, Zierz S. Hearing impairment is common in various phenotypes of the mitochondrial DNA A3243G mutation. Arch Neurol. 2001; 58:1885-1888.","DOI":"10.1001\/archneur.58.11.1885"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Lien LM, Lee HC, Wang KL, Chiu JC, Chiu HC, Wei YH. Involvement of nervous system in maternally inherited diabetes and deafness (MIDD) with the A3243G mutation of mitochondrial DNA. Acta Neurol Scand. 2001; 103:159-165.","DOI":"10.1034\/j.1600-0404.2001.103003159.x"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Wortmann SB, Rodenburg RJ, Backx AP, Schmitt E, Smeitink JAM, Morava E. Early cardiac involvement in children carrying the A3243G mtDNA mutation. Acta Paediatr. 2007; 96:450-451.","DOI":"10.1111\/j.1651-2227.2006.00158.x"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Fayssoil A. Heart diseases in mitochondrial encephalomyopathy, lactic acidosis, and stroke syndrome. Congest Heart Fail. 2009; 15:284-287.","DOI":"10.1111\/j.1751-7133.2009.00108.x"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Fukao T, Kondo M, Yamamoto T, Orii KE, Kondo N. Comparison of mitochondrial A3243G mutation loads in easily accessible samples from a family with maternally inherited diabetes and deafness. Mol Med Rep. 2009; 2:69-72.","DOI":"10.3892\/mmr_00000063"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Olsson C, Johnsen E, Nilsson M, Wilander E, Syv\u00e4nen AC, Lagerstr\u00f6m-Ferm\u00e9r M. The level of the mitochondrial mutation A3243G decreases upon ageing in epithelial cells from individuals with diabetes and deafness. Eur J Hum Genet. 2001; 9:917-921.","DOI":"10.1038\/sj.ejhg.5200742"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Alcubilla-Prats P, Sol\u00e9 M, Botey A, Grau JM, Garrabou G, Poch E. Kidney involvement in MELAS syndrome: Description of 2 cases. Med Clin (Barc). 2017; 148:357-361.","DOI":"10.1016\/j.medcle.2017.04.002"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Li JY, Hsieh RH, Peng NJ, Lai PH, Lee CF, Lo YK, Wei YH. A follow-up study in a Taiwanese family with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes syndrome. J Formos Med Assoc. 2007; 106:528-536.","DOI":"10.1016\/S0929-6646(07)60003-5"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Parikh S, Saneto R, Falk MJ, Anselm I, Cohen BH, Haas R, Medicine Society TM. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol. 2009; 11:414-430.","DOI":"10.1007\/s11940-009-0046-0"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Abe K, Matsuo Y, Kadekawa J, Inoue S, Yanagihara T. Effect of coenzyme Q10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): Evaluation by noninvasive tissue oximetry. J Neurol Sci. 1999; 162:65-68.","DOI":"10.1016\/S0022-510X(98)00296-2"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Hargreaves IP. Coenzyme Q10 as a therapy for mitochondrial disease. Int J Biochem Cell Biol. 2014; 49:105-111.","DOI":"10.1016\/j.biocel.2014.01.020"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Berbel-Garcia A, Barbera-Farre JR, Etessam JP, Salio AM, Cabello A, Gutierrez-Rivas E, Campos Y. Coenzyme Q10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin Neuropharmacol. 2004; 27:187-191.","DOI":"10.1097\/01.wnf.0000137862.67131.bf"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab. 2015; 116:4-12.","DOI":"10.1016\/j.ymgme.2015.06.004"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Ikawa M, Povalko N, Koga Y. Arginine therapy in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Curr Opin Clin Nutr Metab Care. 2020; 23:17-22.","DOI":"10.1097\/MCO.0000000000000610"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Neergheen V, Chalasani A, Wainwright L, Yubero D, Montero R, Artuch R, Iain Hargreaves. Coenzyme Q10 in the treatment of mitochondrial disease. J Inborn Errors Metab Screen. 2017; 5.","DOI":"10.1177\/2326409817707771"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Ferreira F, Gon\u00e7alves Bacelar C, Lisboa-Gon\u00e7alves P, Paulo N, Quental R, Nunes AT, Silva R, Tavares I. Renal manifestations in adults with mitochondrial disease from the mtDNA m.3243A&gt;G pathogenic variant. Nefrologia. 2023; 43:1-7.","DOI":"10.1016\/j.nefro.2023.03.004"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Lock JH, Irani NK, Newman NJ. Neuro-ophthalmic manifestations of mitochondrial disorders and their management. Taiwan J Ophthalmol. 2021; 11:39-52.","DOI":"10.4103\/tjo.tjo_68_20"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Yu-Wai-Man P, Griffiths PG, Gorman GS, <i>et al<\/i>. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010; 133:771-786.","DOI":"10.1093\/brain\/awq007"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Yahata N, Goto YI, Hata R. Optimization of mtDNA-targeted platinum TALENs for bi-directionally modifying heteroplasmy levels in patient-derived m.3243A&gt;G-iPSCs. Mol Ther Nucleic Acids. 2025; 36:102521.","DOI":"10.1016\/j.omtn.2025.102521"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Mok BY, de Moraes MH, Zeng J, Bosch DE, Kotrys AV, Raguram A, Hsu F, Radey MC, Peterson SB, Mootha VK, Mougous JD, Liu DR. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. 2020; 583:631-637.","DOI":"10.1038\/s41586-020-2477-4"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Steele H, Gomez-Duran A, Pyle A, <i>et al<\/i>. Metabolic effects of bezafibrate in mitochondrial disease. EMBO Mol Med. 2020; 12:e11589.","DOI":"10.15252\/emmm.201911589"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, Cohen BH. Mitochondrial disease: A practical approach for primary care physicians. Pediatrics. 2007; 120:1326-1333.","DOI":"10.1542\/peds.2007-0391"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Fiedorczuk K, Letts JA, Degliesposti G, Kaszuba K, Skehel M, Sazanov LA. Atomic structure of the entire mammalian mitochondrial complex I. Nature. 2016; 538:406-410.","DOI":"10.1038\/nature19794"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Geromel V, Darin N, Chr\u00e9tien D, B\u00e9nit P, DeLonlay P, R\u00f6tig A, Munnich A, Rustin P. Coenzyme Q10 and idebenone in the therapy of respiratory chain diseases: Rationale and comparative benefits. Mol Genet Metab. 2002; 77:21-30.","DOI":"10.1016\/S1096-7192(02)00145-2"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/14\/4\/14_2025.01051\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:42:05Z","timestamp":1764996125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/14\/4\/14_2025.01051\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,30]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2025.01051","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,30]]},"article-number":"2025.01051"}}